HK1153678A1 - Use of hsp70 as a regulator of enzymatic activity hsp70 - Google Patents

Use of hsp70 as a regulator of enzymatic activity hsp70

Info

Publication number
HK1153678A1
HK1153678A1 HK11108223.9A HK11108223A HK1153678A1 HK 1153678 A1 HK1153678 A1 HK 1153678A1 HK 11108223 A HK11108223 A HK 11108223A HK 1153678 A1 HK1153678 A1 HK 1153678A1
Authority
HK
Hong Kong
Prior art keywords
hsp70
enzymatic activity
regulator
bmp
enzyme
Prior art date
Application number
HK11108223.9A
Other languages
English (en)
Inventor
Thomas Kirkegaard Jensen
Marja Helena Jaattela
Original Assignee
Orphazyme Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orphazyme Aps filed Critical Orphazyme Aps
Publication of HK1153678A1 publication Critical patent/HK1153678A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01003—Adenosine triphosphatase (3.6.1.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK11108223.9A 2008-06-26 2011-08-08 Use of hsp70 as a regulator of enzymatic activity hsp70 HK1153678A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200800885 2008-06-26
PCT/DK2009/050151 WO2009155936A1 (en) 2008-06-26 2009-06-26 Use of hsp70 as a regulator of enzymatic activity

Publications (1)

Publication Number Publication Date
HK1153678A1 true HK1153678A1 (en) 2012-04-05

Family

ID=41124251

Family Applications (3)

Application Number Title Priority Date Filing Date
HK11108223.9A HK1153678A1 (en) 2008-06-26 2011-08-08 Use of hsp70 as a regulator of enzymatic activity hsp70
HK13101699.7A HK1175395A1 (en) 2008-06-26 2013-02-06 Use of hsp70 as a regulator of enzymatic activity hsp70
HK14104008.6A HK1190644A1 (en) 2008-06-26 2014-04-25 Use of hsp70 as a regulator of enzymatic activity hsp70

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK13101699.7A HK1175395A1 (en) 2008-06-26 2013-02-06 Use of hsp70 as a regulator of enzymatic activity hsp70
HK14104008.6A HK1190644A1 (en) 2008-06-26 2014-04-25 Use of hsp70 as a regulator of enzymatic activity hsp70

Country Status (18)

Country Link
US (8) US8540985B2 (de)
EP (6) EP2659904B1 (de)
JP (2) JP5616336B2 (de)
CN (2) CN102123729B (de)
AT (1) ATE552010T1 (de)
AU (1) AU2009262670B2 (de)
BR (2) BRPI0914684C1 (de)
CA (2) CA3004867C (de)
DK (4) DK3578195T3 (de)
ES (4) ES2963910T3 (de)
FI (1) FI3578195T3 (de)
HK (3) HK1153678A1 (de)
HU (1) HUE025852T2 (de)
IL (2) IL209979A (de)
PL (3) PL2659904T3 (de)
PT (3) PT2484371E (de)
RU (2) RU2521672C2 (de)
WO (1) WO2009155936A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
EP2659904B1 (de) 2008-06-26 2015-09-16 Orphazyme APS Verwendung von Hsp70 als Regler der enzymatischen Aktivität
EP3626255A1 (de) * 2010-11-30 2020-03-25 Orphazyme A/S Procédés pour accroître l'activité cellulaire de hsp70
WO2012177778A1 (en) * 2011-06-20 2012-12-27 Mount Sinai School Of Medicine Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders
WO2013003593A1 (en) * 2011-06-28 2013-01-03 Alternative Innovative Technologies Llc Methods of use of hsp70 for increased performance or hsp70 related disorders
WO2013006076A1 (en) * 2011-07-04 2013-01-10 New York University The use of intranasally administered hsp70 protein to treat neurodegenerative diseases
ES2791760T3 (es) 2011-09-07 2020-11-05 Sinai School Medicine Ceramidasa y diferenciación celular
HUP1100535A2 (en) * 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
HUP1100534A2 (en) * 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
WO2013101509A2 (en) * 2011-12-15 2013-07-04 Alternative Innovative Technologies Llc Hsp70 fusion protein conjugates and uses thereof
CN104115478B (zh) 2011-12-16 2016-04-20 利-考股份有限公司 发光成像扫描仪
EP2800577A2 (de) * 2012-01-05 2014-11-12 Beech Tree Labs Inc. Verfahren zur behandlung von krebs durch verabreichung von geringen mengen von hitzeschock-protein 70 (hsp70)
WO2013130654A1 (en) 2012-02-29 2013-09-06 Coyote Pharmaceuticals, Inc. Gga and gga derivatives, compositions thereof and methods for treating neurodegenerative diseases including paralysis including them
EP2852399B1 (de) * 2012-05-21 2020-02-19 The Regents of The University of Colorado, A Body Corporate Ledgf-peptide und formulierungen daraus zur behandlung von degenerativen erkrankungen
LT2854910T (lt) 2012-06-01 2020-05-25 Icahn School Of Medicine At Mount Sinai Ceramido lygiai infekcijos gydymo ir prevencijos metu
JP6124046B2 (ja) * 2012-07-06 2017-05-10 日立工機株式会社 背負式電源
US9119808B1 (en) 2012-10-08 2015-09-01 Coyote Pharmaceuticals, Inc. Treating neurodegenerative diseases with GGA or a derivative thereof
WO2014107686A1 (en) * 2013-01-07 2014-07-10 Coyote Pharmaceuticals, Inc. Methods for treating neuron damage
PT2968479T (pt) 2013-03-14 2019-08-07 Icahn School Med Mount Sinai Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização
CN104237168B (zh) * 2013-06-21 2017-12-12 国家纳米科学中心 一种检测液体样品中外囊体的方法
PL3193840T3 (pl) * 2014-09-15 2021-12-06 Orphazyme A/S Preparat arimoklomolu
US20160270458A1 (en) * 2015-03-16 2016-09-22 Mean Green Products, LLC Cooling backpack apparatus
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP3427060A4 (de) 2016-03-07 2019-12-18 CFGenome, LLC Nichtinvasive molekulare kontrollen
EP3442530A1 (de) 2016-04-13 2019-02-20 Orphazyme A/S Hitzeschockproteinen und cholesterinhomöostase
ES2831764T3 (es) * 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
CN108026142B (zh) * 2016-07-04 2022-07-08 艾凯奇（厦门）生物科技有限公司 孤儿核受体Nur77的配体及其用途
WO2018067854A1 (en) * 2016-10-06 2018-04-12 Ramp Research, Llc Methods, compositions, and kits involving alteration of the chaperone protein axis in a subject
CA3063974A1 (en) 2017-05-24 2018-11-29 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
US11801284B2 (en) 2017-12-13 2023-10-31 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating motor neuron diseases
CA3101241A1 (en) * 2018-05-28 2019-12-05 Orphazyme A/S Hsp70 protein levels in pbmc samples as biomarker for disease
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
CN109867715B (zh) * 2019-02-28 2022-06-17 中国科学院昆明植物研究所 一种叶绿体蛋白和ATPase酶活性突变体在提高植物抗逆性中的应用
WO2021113464A1 (en) * 2019-12-04 2021-06-10 Friedman Simon Protein blocking assembly and methods of making and using
EP4171559A1 (de) * 2020-06-24 2023-05-03 Zevra Denmark A/S Arimoclomol zur behandlung von morbus gaucher
CN112301000B (zh) * 2020-11-16 2023-04-25 吉林大学 一种能将应激信号转变为egfp荧光信号的报告细胞系
KR20230128462A (ko) * 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
WO2022115612A1 (en) * 2020-11-25 2022-06-02 Lysosomal and Rare Disorders Research and Treatment Center, Inc. Inhibition of caspase pathway as a treatment for lysosomal storage disorders
CN115192712B (zh) * 2022-07-05 2023-08-01 四川大学华西第二医院 Hsp抑制剂在制备胚胎神经系统畸形治疗的产品中的应用

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645243B2 (en) * 1988-03-18 1994-01-13 General Hospital Corporation, The Human heat shock factor
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
ATE212378T1 (de) 1993-06-04 2002-02-15 Whitehead Biomedical Inst Stressproteine und ihre verwendung
EP0751957B1 (de) 1994-03-21 2004-02-25 Rijksuniversiteit Utrecht Peptidfragmente von mikrobiellen stressproteinen und daraus hergestellte pharmazeutische zusammensetzungen für die behandlung und vorbeugung von entzündungserkrankungen
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
US5962313A (en) 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US6066716A (en) 1996-09-20 2000-05-23 University Of New Mexico Purified heat shock protein complexes
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
KR20010040389A (ko) 1998-01-23 2001-05-15 내셔날 쥬이쉬 메디칼 앤드 리서치 센터 열 충격 단백질을 사용하여 염증성 질환을 치료하는 방법
ES2285832T3 (es) 1998-02-20 2007-11-16 Univ Miami Complejo de peptido antigenico-proteina de choque termico modificada.
CA2325735C (en) 1998-03-27 2013-06-04 Gabriele Multhoff Hsp70 protein for the treatment of tumours, cancer or infectious diseases through nk-cell activation
FR2777890B1 (fr) 1998-04-22 2000-12-29 Roussy Inst Gustave Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
HU226617B1 (en) 1998-12-14 2009-04-28 Cytrx Corp Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
WO2001017554A1 (en) 1999-09-10 2001-03-15 Fordham University Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
US20020039583A1 (en) 1999-09-30 2002-04-04 Subjeck John R. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US20030236300A1 (en) 1999-10-27 2003-12-25 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
AU1582801A (en) 1999-11-05 2001-06-06 Board Of Regents Of The University Of Nebraska, The Methods and compositions for protection against bovine herpesvirus
US6964851B2 (en) 1999-12-07 2005-11-15 Stressgen Biotechnologies Corp. Compositions and methods for detecting stress-inducible proteins
GB9930443D0 (en) 1999-12-22 2000-02-16 King S College London Novel use of heat shock proteins
US20020127219A1 (en) 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
US20010034042A1 (en) 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
AU2001227960A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Heat shock/stress protein complexes as vaccines against neurodegenerative disorders
WO2001052877A1 (en) 2000-01-21 2001-07-26 University Of Connecticut Health Center Compositions and methods to treat neurodegenerative disorders
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
WO2002011669A2 (en) 2000-08-07 2002-02-14 Antigenics, Llc Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof
AU2002212236A1 (en) 2000-09-13 2002-03-26 Gabriele Multhoff An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
CA2422867A1 (en) 2000-09-15 2002-04-25 University Of Connecticut Health Center Improved formulations using heat shock/stress protein-peptide complexes
US20020172682A1 (en) 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
IT1319277B1 (it) 2000-10-24 2003-09-26 Chiesi Farma Spa Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
WO2002041921A2 (en) 2000-11-03 2002-05-30 The Board Of Regents Of The University Of Nebraska Compositions for protection against bovine viral diseases
EP1209226A3 (de) 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Reifen von dendritischen Zellen durch die Verwendung von rekombinante Hitzeschock-Protein 70 (hsp70)
US20020142299A1 (en) 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
EP1368039A4 (de) * 2001-02-20 2006-03-29 Uab Research Foundation Aminoglycosid-behandlung für lysosomale speicherkrankheiten
JP4384489B2 (ja) 2001-08-20 2009-12-16 ユニバーシティー オブ コネティカット ヘルス センター 癌及び感染性疾患の治療に有用な熱ショックタンパク質又はα−２−マクログロブリンを含む組成物の調製方法
EP1430076A2 (de) 2001-09-27 2004-06-23 I.D.M. Immuno-Designed Molecules Polypeptide aus induziertbarem hsp70 und ihre pharmazeutischen zusammensetzungen
HU0103939D0 (en) 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
GB0123756D0 (en) 2001-10-03 2001-11-21 King S College London A novel chaperone-type of adjuvant for vaccination - Basic 1
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
ITMI20012573A1 (it) 2001-12-06 2003-06-06 D B P Dev Biotechonologica L P Gli acilsalicilati:una nuova classe di induttori di risposta heat shock
NZ533795A (en) 2002-01-11 2006-03-31 Biorex Kutato Fejlesztoe Kft Carboxamidine derivatives and their use in the treatment of vascular diseases
AU2003218639A1 (en) * 2002-01-24 2003-09-02 Universiteit Gent Tumour treatment compositions comprising hsp70 and tumour necrosis factor
EP1572933A4 (de) 2002-02-13 2007-09-05 Univ Duke Modulation der immunantwort durch polypeptide als antwort auf nichtpeptidischen bindungsstress
IL148401A0 (en) 2002-02-26 2002-09-12 Hadasit Med Res Service Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
AU2003224880A1 (en) 2002-04-05 2003-10-27 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
JP3912790B2 (ja) 2002-04-12 2007-05-09 三菱電機株式会社 車両用交流発電機
CA2483449A1 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2004035602A2 (en) 2002-05-02 2004-04-29 University Of Connecticut Health Center Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines
JP2005533015A (ja) 2002-05-02 2005-11-04 ユニバーシティー オブ コネティカット ヘルス センター 抗体療法の有効性を増強するための熱ショックタンパク質の使用
GB0216414D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
EP1578364A4 (de) 2002-09-16 2011-06-08 Genentech Inc Zusammensetzungen und verfahren zur behandlung von erkrankungen des immunsystems
ES2396231T3 (es) 2003-05-21 2013-02-20 Biotech Tools S.A. Complejo peptídico
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
DE60335549D1 (de) 2003-11-12 2011-02-10 Alfa Biogene Internat B V Gewinnung von Hitzeschockproteinen
WO2005051331A2 (en) 2003-11-25 2005-06-09 Mount Sinai School Of Medicine Of New York University Chaperone-based therapy for niemann-pick disease
JP4898452B2 (ja) 2003-12-05 2012-03-14 マルチミューン ジーエムビーエイチ 治療および診断用抗Ｈｓｐ７０抗体
US20060009520A1 (en) 2004-05-12 2006-01-12 Tall Alan R Retinoid-based methods for altering macrophage cholesterol
WO2005120558A2 (en) 2004-05-25 2005-12-22 University Of Connecticut Health Center Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
JP2008523055A (ja) 2004-12-10 2008-07-03 ゼルニケ ビジネス サポート ビー．ヴィー． 熱ショックタンパク質（ｈｓｐ）および上室性不整脈
RU2283128C1 (ru) * 2005-04-05 2006-09-10 Сергей Викторович Луценко Способ получения препарата белка из семейства стрессовых и препарат белка hsp70, полученный этим способом
EP1888068B1 (de) 2005-06-08 2014-05-21 Amicus Therapeutics, Inc. Behandlung von zns-erkrankungen in zusammenhang mit mutationen bei für lysosomale enzyme kodierenden genen
WO2007041285A2 (en) 2005-09-29 2007-04-12 Viral Genetics, Inc. Complexes of inactivated pepsin fraction and heat shock protein
SI2404919T1 (sl) 2005-11-08 2013-12-31 Vertex Pharmaceuticals Incorporated Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto
US20080039400A1 (en) * 2006-01-24 2008-02-14 Universiteit Utrecht Uu Holding B.V. Treatment and prevention of inflammatory bowel diseases
NZ570103A (en) 2006-01-26 2011-11-25 Foldrx Pharmaceuticals Inc Compounds and methods for modulating protein trafficking
AU2007253694A1 (en) 2006-05-19 2007-11-29 The Scripps Research Institute Treatment of protein misfolding
PT2040548E (pt) * 2006-06-23 2012-08-02 Amicus Therapeutics Inc Método para o tratamento de distúrbios neurológicos através do aumento da atividade da -glucocerebrosidase
WO2008005937A2 (en) 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
TW200824678A (en) 2006-08-11 2008-06-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
JP2010503616A (ja) 2006-08-29 2010-02-04 フォルマンテク．・カンパニー， リミテッド アポトーシスを抑制するための薬学的組成物および前記薬学的組成物をデリバーするための方法
CA2671049A1 (en) * 2006-12-01 2008-06-12 Cytrx Corporation Stroke recovery
CA2680063A1 (en) 2007-02-23 2008-08-28 University Of Florida Research Foundation, Inc. Compositions and methods for treating glycogen storage diseases
WO2008112525A2 (en) 2007-03-09 2008-09-18 Link Medicine Corporation Treatment of lysosomal storage diseases
GB0705626D0 (en) 2007-03-23 2007-05-02 Royal Veterinary College Method for enhancing sperm survival
WO2008127680A2 (en) 2007-04-11 2008-10-23 The Jackson Laboratory Diagnosis and treatment of diseases caused by misfolded proteins
WO2008128106A1 (en) 2007-04-13 2008-10-23 Amicus Therapeutics, Inc. Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
AU2008245578A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
TW200901958A (en) 2007-05-04 2009-01-16 Cytrx Corp Diabetic wound healing
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
WO2009008719A2 (en) 2007-07-06 2009-01-15 Universiteit Utrecht Holding B.V. Treatment and prevention of inflammatory diseases and autoimmune diseases
JP2010538655A (ja) 2007-09-12 2010-12-16 アナフォア インコーポレイテッド 自己免疫疾患についてのｈｓｐ７０に基づく治療
EP2252288A1 (de) 2007-11-21 2010-11-24 Summit Corporation Plc Behandlung von proteinfaltungsstörungen
EA201000895A1 (ru) 2007-11-29 2010-12-30 Де Хоспитал Фо Сик Чилдрен Композиции и способы для лечения лизосомных болезней
JP5501981B2 (ja) 2008-01-30 2014-05-28 ジェロン・コーポレーション 既知組成培地中で細胞を培養するための合成表面
WO2009095452A1 (en) 2008-01-31 2009-08-06 Crystax Pharmaceuticals, S.L. Crystal structure of the atpase domain of proteins of the hsp70 family
AU2009332930A1 (en) 2008-02-01 2009-08-13 The Scripps Research Institute Methods for treating a condition characterized by dysfunction in protein homeostasis
EP3778652A1 (de) 2008-05-07 2021-02-17 BioMarin Pharmaceutical Inc. Auf lysosomen gerichtete peptide und verwendungen davon
WO2009137796A2 (en) 2008-05-08 2009-11-12 Northwestern University Method of regulating the heat shock response
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
EP2659904B1 (de) 2008-06-26 2015-09-16 Orphazyme APS Verwendung von Hsp70 als Regler der enzymatischen Aktivität
EP2323652A2 (de) 2008-08-06 2011-05-25 Summit Corporation Plc Behandlung von lysosomalen speicherkrankheiten und anderen proteostatischen krankheiten
WO2010022461A1 (en) 2008-08-29 2010-03-04 Children, Youth And Women's Health Service Sulphated sugars to increase activity of sulphatases en lysosomal storage disorders
AR073709A1 (es) 2008-09-29 2010-11-24 Vertex Pharma Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico
WO2010053655A2 (en) 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
EP2391229B1 (de) 2009-01-29 2015-07-15 Alfa Biogene International B.V. "functional food"-produkt, welches ein hitzeschockprotein aus alfalfa oder ein hydrolysat davon enthält
EP2218458A1 (de) 2009-02-13 2010-08-18 Fondazione Telethon Moleküle mit der Fähigkeit zur Modulierung der Expression von mindestens einem am Abbaupfad beteiligten Gen und Verwendungen dafür
WO2010102988A1 (en) 2009-03-10 2010-09-16 Alfa Biogene International B.V. Skin care product
GB0906159D0 (en) 2009-04-09 2009-05-20 Summit Corp Plc Drug combination for the treatment of proteostatic diseases
EP3075386B1 (de) 2009-06-17 2019-10-16 BioMarin Pharmaceutical Inc. Formulierungen für lysosomale enzyme
CN105126086B (zh) 2009-07-28 2019-05-14 夏尔人类遗传性治疗公司 用于治疗戈谢病的组合物和方法
WO2011019763A2 (en) 2009-08-10 2011-02-17 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
US20110081428A1 (en) 2009-09-16 2011-04-07 The Buck Institute For Age Research Use of thioflavin-like compounds to increase life span and/or health span
US8628979B2 (en) 2009-10-21 2014-01-14 Pronota N.V. MCAM as a biomarker for fluid homeostasis
US8609416B2 (en) 2009-12-18 2013-12-17 Ventria Bioscience Methods and compositions comprising heat shock proteins
US20130209549A1 (en) 2010-07-21 2013-08-15 University Of South Florida Materials and methods for treating neurodegenerative diseases
EP3626255A1 (de) 2010-11-30 2020-03-25 Orphazyme A/S Procédés pour accroître l'activité cellulaire de hsp70
WO2013006076A1 (en) 2011-07-04 2013-01-10 New York University The use of intranasally administered hsp70 protein to treat neurodegenerative diseases
WO2013148333A1 (en) 2012-03-28 2013-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Salicylic acid derivatives useful as glucocerebrosidase activators
SG11201502989XA (en) 2012-11-05 2015-05-28 Genzyme Corp Compositions and methods for treating proteinopathies
CN112079929A (zh) 2012-11-21 2020-12-15 武汉友芝友生物制药有限公司 双特异性抗体
PL3193840T3 (pl) 2014-09-15 2021-12-06 Orphazyme A/S Preparat arimoklomolu

Also Published As

Publication number Publication date
CN102123729A (zh) 2011-07-13
EP4285909A3 (de) 2024-02-28
CA2728363A1 (en) 2009-12-30
PT2318032E (pt) 2012-06-19
CA2728363C (en) 2019-02-19
BRPI0914684A2 (pt) 2017-06-06
PT2484371E (pt) 2015-03-03
US9884058B2 (en) 2018-02-06
US10543204B2 (en) 2020-01-28
PL2318032T3 (pl) 2012-08-31
DK2484371T3 (en) 2015-03-02
US20160263096A1 (en) 2016-09-15
IL209979A (en) 2016-02-29
ATE552010T1 (de) 2012-04-15
JP2014132016A (ja) 2014-07-17
EP2659904B1 (de) 2015-09-16
EP4285909A2 (de) 2023-12-06
DK2318032T3 (da) 2012-06-11
AU2009262670B2 (en) 2013-06-20
IL209979A0 (en) 2011-02-28
ES2963910T3 (es) 2024-04-03
CA3004867A1 (en) 2009-12-30
US9289472B2 (en) 2016-03-22
EP3578195B1 (de) 2023-08-09
CN104586846B (zh) 2017-10-24
BRPI0914684C1 (pt) 2021-05-25
JP5860493B2 (ja) 2016-02-16
BR122019024895B8 (pt) 2021-07-27
EP2484371B1 (de) 2014-12-17
IL235342B (en) 2018-11-29
EP3031467B1 (de) 2019-03-06
BRPI0914684B8 (pt) 2020-10-13
US20150004151A1 (en) 2015-01-01
EP2318032B1 (de) 2012-04-04
BR122019024895B1 (pt) 2020-08-18
RU2014116069A (ru) 2015-07-20
RU2571946C2 (ru) 2015-12-27
US20200113888A1 (en) 2020-04-16
PT2659904E (pt) 2016-01-22
RU2011102781A (ru) 2012-08-10
CA3004867C (en) 2020-09-15
US8540985B2 (en) 2013-09-24
CN102123729B (zh) 2015-04-29
EP3031467A1 (de) 2016-06-15
EP2318032A1 (de) 2011-05-11
US11045460B2 (en) 2021-06-29
CN104586846A (zh) 2015-05-06
US11304941B2 (en) 2022-04-19
AU2009262670A1 (en) 2009-12-30
HK1190644A1 (en) 2014-07-11
US20220362234A1 (en) 2022-11-17
US11938125B2 (en) 2024-03-26
FI3578195T3 (fi) 2023-11-08
PL2484371T3 (pl) 2015-05-29
EP2659904A1 (de) 2013-11-06
HK1175395A1 (en) 2013-07-05
BRPI0914684B1 (pt) 2020-09-24
DK2659904T3 (en) 2015-12-07
US20200121668A1 (en) 2020-04-23
ES2385735T3 (es) 2012-07-31
WO2009155936A1 (en) 2009-12-30
DK3578195T3 (da) 2023-10-30
US20140050714A1 (en) 2014-02-20
EP2484371A1 (de) 2012-08-08
JP2011525500A (ja) 2011-09-22
EP3578195A1 (de) 2019-12-11
ES2532083T3 (es) 2015-03-24
US20180185349A1 (en) 2018-07-05
JP5616336B2 (ja) 2014-10-29
PL2659904T3 (pl) 2016-01-29
HUE025852T2 (en) 2016-04-28
US20110286993A1 (en) 2011-11-24
RU2521672C2 (ru) 2014-07-10
ES2555908T3 (es) 2016-01-11

Similar Documents

Publication Publication Date Title
IL235342B (en) Using hsp70 as a regulator of enzymatic activity
PH12017500930A1 (en) Hsp90 inhibitor combinations
AU2009223508A8 (en) Expression of catalase in Trichoderma
TW201129938A (en) Personal mapping system
BR112012021933A2 (pt) método para processamento de soluções de peroxigênio.
MY153871A (en) Isoprene synthase variants for improved microbial production of isoprene
UA98629C2 (ru) Соединения и способ модуляции киназ
MX283562B (es) Induccion y estabilizacion de actividad enzimatica en microorganismos.
EP2296693A4 (de) Zusammensetzungen zur verstärkung der antibakteriellen wirkung von myeloperoxidase und anwendungsverfahren davon
WO2005074655A3 (en) Materials and method for promotion of nerve regeneration
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2011005289A3 (en) Methods and kits for measuring enzyme activity
MY161843A (en) Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
GB201202561D0 (en) Treatment of skin disorders
IL207943A0 (en) Modulation of enzymatic structure, activity, and/or expression level
MX2010001187A (es) Moduladores del receptor ccr9 y metodos para su uso.
MX2009009693A (es) Metodos para activar irs-1 y akt.
MX2012004617A (es) Metodos y composiciones para modular activacion de hepsina de proteina que estimula macrofago.
WO2009105507A3 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
IL192414A0 (en) Siva ubiquitination and/or degradation-related activity and modulators thereof
MY151244A (en) A gene encoding a protein having an ability to enhance a selenate reduction activity
UA35880U (ru) Способ лечения острого токсико-аллергического гепатита
MX2014004027A (es) Activadores de zimogeno.
AU321087S (en) A bottle
MY143752A (en) Regulation of gene expression in plants